| 前收盘价格 | 17.35 |
| 收盘价格 | 17.50 |
| 成交量 | 2,112,975 |
| 平均成交量 (3个月) | 2,085,601 |
| 市值 | 1,239,288,064 |
| 市盈率 (P/E TTM) | 10.38 |
| 预期市盈率 (P/E Forward) | 58.14 |
| 价格/销量 (P/S) | 98.47 |
| 股市价格/股市净资产 (P/B) | 8.44 |
| 52周波幅 | |
| 利润日期 | 12 Nov 2026 |
| 稀释每股收益 (EPS TTM) | -3.04 |
| 流动比率 (MRQ) | 1.16 |
| 营业现金流 (OCF TTM) | -142.86 M |
| 杠杆自由现金流 (LFCF TTM) | -102.50 M |
| 资产报酬率 (ROA TTM) | -30.70% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Omeros Corporation | 混合的 | 看涨 |
AIStockmoo 评分
0.8
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -4.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.83 |
|
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 4.40% |
| 机构持股比例 | 47.30% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Kotler Kevin | 31 Dec 2025 | 905,635 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合